Tech Company Financing Transactions
Zafgen Funding Round
Zafgen, operating out of Boston, secured $33 million from Atlas Venture and Third Rock Ventures.
Transaction Overview
Company Name
Announced On
7/7/2011
Transaction Type
Venture Equity
Amount
$33,000,000
Round
Series C
Investors
Atlas Venture (Peter Barrett)
Third Rock Ventures (Kevin Starr)
Proceeds Purpose
Proceeds from the financing will be used to support development of Zafgen's pipeline and to advance its lead methionine aminopeptidase 2 (MetAP2) inhibitor for the treatment of severe obesity into Phase 2 clinical studies.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
175 Portland St. 4th Floor
Boston, MA 02114
USA
Boston, MA 02114
USA
Phone
Website
Email Address
Overview
Zafgen (NASDAQ: ZFGN) is developing beloranib, a novel obesity therapy that demonstrates a unique mechanism of action, re-establishing balance to the ways the body produces and uses fat stored in adipose tissue.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Jeffrey Hatfield
Chief Financial Officer
Patricia Allen
Chief Medical Officer
Dennis Kim
VP - Bus. Development
Brian McVeigh
VP - Bus. Development
James Vath
Browse more venture capital transactions:
Prev: 7/6/2011: Hawthorne Labs venture capital transaction
Next: 7/7/2011: Virtustream venture capital transaction
Share this article
Where The Data Comes From
We do our best to document every notable VC transaction. All VC database entries on this site are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs